Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,811 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06990126Enrolling by invitation
New tetracycline for drug-resistant bacterial infections
This trial tests a new tetracycline antibiotic (neotetracycline) for treating infections caused by drug-resistant Gram-negative bacteria. It aims to see how well the drug works and what side effects it may have.
Nanjing, JiangsuAges 18 years+ - NCT06751433RecruitingPhase 1/Phase 2
Scar gel study for preventing thick scars
This trial tests a special gel designed to prevent raised, thick scars (hypertrophic scars) after surgery or injury. If you have a new scar from a C-section, breast implant, or clean cut, this study may help reduce scarring.
Osasco, São PauloAges 18–70 - NCT06818994RecruitingPhase 1
Psilocybin therapy for low mood in advanced cancer
This trial tests if a medicine called psilocybin, given with talk therapy, can safely help people with advanced cancer who feel very demoralized. Demoralization is a deep sense of hopelessness or loss of meaning. The goal is to see if this treatment can improve your emotional well-being.
Kingston, OntarioAges 18–70 - NCT07471399Recruiting
Radiofrequency device for temporary face tightening
This study tests a radiofrequency device to tighten facial skin temporarily. It may be a treatment option for people who want non-surgical skin tightening.
SeoulAges 19–65 - NCT07557810Recruiting
Thermal Ablation Plus Drugs for Overactive Thyroid
This trial tests combining heat treatment of the thyroid gland with antithyroid medications to treat primary hyperthyroidism (an overactive thyroid). It may help patients who haven't responded well to standard drugs, had side effects, or want faster symptom relief.
BeijingAges Up to 80 years - NCT06798298Recruiting
Long-term safety study of gene modified T cell treatment
This study is a long-term safety check for people who have already received a gene modified T cell treatment in a previous study sponsored by 2seventy bio or Regeneron Pharmaceuticals. The goal is to monitor your health for years after that treatment to see how well it works and if any side effects appear over time.
Nashville, TennesseeAges 18 years+ - NCT07098663RecruitingPhase 2
Study of MKP10241 for weight loss and diabetes control
This study tests an investigational drug called MKP10241 in healthy people, people with obesity, and people with type 2 diabetes. It aims to see how the drug affects blood sugar, weight, and overall safety. It may be an option if you have obesity or type 2 diabetes managed by diet and/or metformin.
Bayswater, VictoriaAges 18–60 - NCT04861506Recruiting
Clot-removal treatment for blocked blood flow in the leg
This trial tests how safe and effective a clot-removal procedure done through the blood vessels is for people with acute or subacute blocked blood flow in the lower leg. It may help by improving circulation while carefully tracking risks and results.
Hangzhou, ZhejiangAges 18 years+ - NCT01898416RecruitingPhase 2
5-ALA by mouth to reduce regrowth of desmoid tumors
This Phase 2 trial tests whether taking a medicine called 5-ALA by mouth after treatment can lower how often desmoid tumors come back in the same area. If you have a desmoid tumor that can be removed and you meet safety criteria, this study may help determine whether 5-ALA is effective and safe for you.
Tel Aviv, IsraelAges 18 years+ - NCT06676410RecruitingPhase 2
Testing Codivir plus standard HIV treatment in new patients
This trial tests a new investigational drug called Codivir added to standard HIV treatment for people who have never taken HIV medications before. It aims to see if adding Codivir helps control the virus better and is safe.
São PauloAges 18 years+ - NCT05714839RecruitingPhase 1/Phase 2
Belantamab for multiple myeloma
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
Bullhead City, ArizonaAges 18 years+ - NCT07625280RecruitingPhase 3
Twice-nightly treatment for narcolepsy or idiopathic hypersomnia
This study tests whether taking the sleep medicine Xywav two times each night is safe and helps control symptoms better than a placebo. People with narcolepsy or idiopathic hypersomnia may join, including those who have not tried oxybate medicines before.
Los Angeles, CaliforniaAges 18–75 - NCT07481981RecruitingPhase 3
Study of once-daily inhaled TPIP for pulmonary arterial hypertension
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
Santa Barbara, CaliforniaAges 18–75 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Chandler, ArizonaAges 55–90 - NCT07447986RecruitingPhase 2
Testing a New Injection for Lupus (SLE)
This study tests a new injectable medicine (SG301) for people with lupus (SLE) whose current treatments are not working well enough or cause side effects. It aims to see if this targeted therapy can better control lupus symptoms.
Beijing, Beijing MunicipalityAges 18–70 - NCT05776927RecruitingPhase 3
Testing a new inhaler for teens with asthma
This trial tests a new combination inhaler (QVM149) against a standard one (Advair) in teenagers with asthma that isn't well controlled by their current medicine. It aims to see if the new inhaler works better.
Germiston, GautengAges 12–17 - NCT07365319RecruitingPhase 2/Phase 3
New drug combo for stage 4 lung cancer
This trial tests a new drug called EIK1001 combined with standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who have not been treated before. The goal is to see if adding EIK1001 helps shrink tumors more than the current standard treatment.
Daphne, AlabamaAges 18 years+ - NCT06865651RecruitingPhase 2
Study of Remibrutinib for chronic hives not helped by antihistamines
This trial tests an experimental drug called Remibrutinib for people with chronic hives (urticaria) that are not well controlled with standard antihistamines. The goal is to see if the drug reduces symptoms like itching and wheals.
North Miami Beach, FloridaAges 18 years+ - NCT07565285RecruitingPhase 2
Combination Treatment for Operable Stage III Skin Melanoma
This study tests whether combining a new drug called PRTX007-003 with pembrolizumab (an immunotherapy) can help prevent melanoma from returning after surgery. You would receive both treatments after your tumor is surgically removed.
Waratah, New South WalesAges 18 years+ - NCT05977673RecruitingPhase 2
Tislelizumab for untreated Hodgkin lymphoma when chemo isn’t suitable
This Phase 2 trial tests tislelizumab (an immune therapy) in people with newly diagnosed classical Hodgkin lymphoma who cannot safely get standard chemotherapy. It aims to see how well the treatment works and whether it is safe for older adults and others with health limits.
Alessandria, ITAges 65 years+ - NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Birmingham, AlabamaAges 12–100 - NCT07221851RecruitingPhase 3
Weekly vs daily growth hormone for short stature in children
This trial tests a weekly growth hormone injection (lonapegsomatropin) compared to the standard daily growth hormone shot in children with short stature due to certain conditions. It aims to see if the weekly shot works as well or better and is safe.
Palo Alto, CaliforniaAges 2–17 - NCT07378644RecruitingPhase 2/Phase 3
Testing SKY-0515 for Huntington's disease
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
Englewood, ColoradoAges 25 years+ - NCT07431177RecruitingPhase 2
Study of an investigational drug for non-segmental vitiligo
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
Birmingham, AlabamaAges 18–99
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,811 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.